Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, Ghilardi C, Scanziani E, Canesi S, Barbera MC, Craparotta I, Bolis M, Fruscio R, Grasselli C, Ceruti T, Zucchetti M, Patterson JC, Lu RA, Yaffe MB, Ridinger M, Damia G, Guffanti F. Chiappa M, et al. Among authors: zucchetti m. Cell Death Dis. 2024 Jul 22;15(7):521. doi: 10.1038/s41419-024-06894-1. Cell Death Dis. 2024. PMID: 39039067 Free PMC article.
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Ceruti T, Frapolli R, Ghilardi C, Decio A, Dellavedova G, Tommasi S, Zucchetti M, Mangoni AA. Ceruti T, et al. Among authors: zucchetti m. Molecules. 2023 Dec 13;28(24):8056. doi: 10.3390/molecules28248056. Molecules. 2023. PMID: 38138547 Free PMC article.
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts.
Demuytere J, Carlier C, Van de Sande L, Hoorens A, De Clercq K, Giordano S, Morosi L, Matteo C, Zucchetti M, Davoli E, Van Dorpe J, Vervaet C, Ceelen W. Demuytere J, et al. Among authors: zucchetti m. Int J Nanomedicine. 2024 Jan 17;19:429-440. doi: 10.2147/IJN.S424045. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38260242 Free PMC article.
A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice.
De Angelis ML, Francescangeli F, Aricò E, Verachi P, Zucchetti M, Matteo C, Petricci E, Pilozzi E, Orienti I, Boe A, Eramo A, Rossi R, Corati T, Macchia D, Pacca AM, Zeuner A, Baiocchi M. De Angelis ML, et al. Among authors: zucchetti m. J Exp Clin Cancer Res. 2024 Nov 5;43(1):296. doi: 10.1186/s13046-024-03213-6. J Exp Clin Cancer Res. 2024. PMID: 39497135 Free PMC article.
Differential effect of asparagine and glutamine removal on three adenocarcinoma cell lines.
Pessino G, Lonati L, Scotti C, Calandra S, Cazzalini O, Iaria O, Previtali A, Baiocco G, Perucca P, Tricarico A, Vetro M, Stivala LA, Ganini C, Cancelliere M, Zucchetti M, Guardamagna I, Maggi M. Pessino G, et al. Among authors: zucchetti m. Heliyon. 2024 Aug 3;10(15):e35789. doi: 10.1016/j.heliyon.2024.e35789. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170541 Free PMC article.
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol.
Rizzari C, Möricke A, Valsecchi MG, Conter V, Zimmermann M, Silvestri D, Attarbaschi A, Niggli F, Barbaric D, Stary J, Elitzur S, Cario G, Vinti L, Boos J, Zucchetti M, Lanvers-Kaminsky C, von Stackelberg A, Biondi A, Schrappe M. Rizzari C, et al. Among authors: zucchetti m. Hemasphere. 2023 Jun 1;7(6):e893. doi: 10.1097/HS9.0000000000000893. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37275740 Free PMC article.
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
Matteo C, Orienti I, Eramo A, Zeuner A, Ferrari M, Passoni A, Bagnati R, Ponzo M, Bello E, Zucchetti M, Frapolli R. Matteo C, et al. Among authors: zucchetti m. Pharmaceutics. 2024 Mar 12;16(3):387. doi: 10.3390/pharmaceutics16030387. Pharmaceutics. 2024. PMID: 38543281 Free PMC article.
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Dalla Pozza L, Elitzur S, Silvestri D, Locatelli F, Möricke A, Engstler G, Smisek P, Bodmer N, Barbaric D, Izraeli S, Rizzari C, Boos J, Buldini B, Zucchetti M, von Stackelberg A, Matteo C, Lehrnbecher T, Lanvers-Kaminsky C, Cazzaniga G, Gruhn B, Biondi A, Schrappe M. Conter V, et al. Among authors: zucchetti m. J Clin Oncol. 2024 Mar 10;42(8):915-926. doi: 10.1200/JCO.23.01388. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096462
213 results